Sanofi provides update on MOBILIZE phase 3 study of riliprubart in chronic inflammatory demyelinating polyneuropathy
Sanofi has announced the discontinuation of its Phase 3 MOBILIZE study evaluating…
Harbour BioMed Announces NMPA Acceptance for the Treatment of Advanced Solid Tumors
Harbour BioMed has announced that China’s National Medical Products Administration (NMPA) has…
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Antag Therapeutics has appointed obesity treatment expert Philip Just Larsen as Chief…
Matt Bonam appointed as Executive Director at the BHF Data Science Centre
Matt Bonam has been appointed Executive Director of the BHF Data Science…
Pfizer Reaches Three Settlement Agreements for VYNDAMAX
Pfizer has reached settlement agreements with multiple generic manufacturers over VYNDAMAX (tafamidis),…
FDA accepts application for Roche’s Gazyva/Gazyvaro for the treatment of the most common form of lupus
The FDA has accepted Roche’s supplemental application for Gazyva/Gazyvaro as a treatment…
Sanofi to acquire Dynavax
Sanofi has announced an agreement to acquire Dynavax Technologies Corporation, a publicly…
Ardelyx Announces Changes to the Executive Leadership Team
Ardelyx, a biopharmaceutical company founded with a mission to discover, develop and…
GSK Partners with Hengrui Pharma to Advance COPD and Oncology Drug Pipeline
GSK plc announced it has entered into agreements with Hengrui Pharma to…
Roche Announces Retirement of Key Executives
Roche announced that Johannes (Hans) Clevers (1957), M.D., Ph.D., Head of Roche…
